Gilder Gagnon Howe & CO LLC Tarsus Pharmaceuticals, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $8.56 Billion
- Q4 2024
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 404,237 shares of TARS stock, worth $16.7 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
404,237
Previous 7,047
5636.3%
Holding current value
$16.7 Million
Previous $231,000
9589.18%
% of portfolio
0.26%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TARS
# of Institutions
201Shares Held
40.5MCall Options Held
72.7KPut Options Held
313K-
Black Rock Inc. New York, NY3.27MShares$135 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.24MShares$134 Million2.92% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.53MShares$105 Million5.35% of portfolio
-
Jennison Associates LLC2.5MShares$103 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$93.1 Million9.38% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.1B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...